PATENT CLAIM ANALYSIS

Application Number: 16327643
Application Type: Utility
Filing Date: 2019-02
Publication Date: 2019-06
Patent Classification: ["514", "233200"]

Abstract:
The present invention relates to the use of PIKfyve inhibitors to inhibit RANKL/RANK signaling and related compositions and methods.

Claim (Index 8):
The method of  claim 7 , wherein the primary cancer is selected from the group consisting of lymphoma, multiple myeloma, breast cancer and prostate cancer.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 99.0
- Lexical Diversity: 1.11111
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15524844', '15213829', '15113154', '14368080', '11705689']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.813332334204886
- 35 USC 102 Novelty (BERT): 0.5239287290395042
- Combined Prediction Score: 0.7843919736883479
- Mean Citation Score: 285.311098
- Max Citation Score: 322.0196200000001
- Similarity Product: 196.75765430887944

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test